Theriva Biologics, Inc. (TOVX)
NYSEAMERICAN: TOVX · Real-Time Price · USD
0.4830
+0.0060 (1.26%)
Jul 18, 2025, 4:00 PM - Market closed

Theriva Biologics Stock Forecast

Stock Price Forecast

There is currently no analyst price target forecast available for Theriva Biologics.

Price Target: n/a
Analyst Consensus: Hold
TargetLowAverageMedianHigh
Pricen/an/an/an/a
Changen/an/an/an/a

Analyst Ratings

According to 1 stock analyst, the rating for Theriva Biologics is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.

Recommendation Trends

RatingMay '25Jun '25Jul '25
Strong Buy000
Buy000
Hold111
Sell000
Strong Sell000
Total111

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Maxim Group
Maxim Group
Hold
Downgrades
n/a
HoldDowngradesn/an/aMay 8, 2025
Maxim Group
Maxim Group
Strong Buy
Maintains
$25$6
Strong BuyMaintains$25$6+1,142.24%Nov 13, 2024
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
from 55.14M
Revenue Next Year
n/a
EPS This Year
-5.63
from -19.03
EPS Next Year
-5.90
from -5.63
Fiscal YearFY 2020FY 2021FY 2022FY 2023FY 2024FY 2025FY 2026FY 2027FY 2028FY 2029
Period EndingDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026Dec 31, 2027Dec 31, 2028Dec 31, 2029
Revenue
---26.24M55.14M
Revenue Growth
----110.11%---
EPS
-165.13-47.57-32.66-28.48-19.03-5.63-5.90-4.89
EPS Growth
--------
Forward PE
--------
No. Analysts
-----333
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue20252026202720282029
Highn/an/an/a
Avgn/an/an/a
Lown/an/an/a

Revenue Growth

Revenue Growth20252026202720282029
High---
Avg---
Low---

EPS Forecast

EPS202520262027
High-5.80-6.07-5.03
Avg-5.63-5.90-4.89
Low-5.41-5.66-4.69

EPS Growth

EPS Growth202520262027
High---
Avg---
Low---
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.